Update launch ChondroCelect (Tigenix) and status of reimbursement applications http://tiny.cc/FRRhS
posted 14 hours ago
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
Pharmaneuroboost (PNB) reported today that the results of it’s phase II Proof-of-Concept study with PNB01 in Major Depression will be presented at the 18th European Congress of Psychiatry on March 2nd in Munich.
“The results are impressive and promising”, says Chief Investigator Alan Wade (Glasgow), who has a longstanding expertise in antidepressant clinical research, and who will be presenting the data personally. “Antidepressant treatment still can benefit from substantial improvement in efficacy and speed of onset”, Wade continues, “and the results obtained with PNB01 in this double-blind randomized study may represent a breakthrough in this respect, if further confirmed”.
PNB01 is the first of two front-running proprietary projects of Pharmaneuroboost. “We are very happy with the positive results of the Proof-of-Concept study, and are looking forward to starting phase III development soon”, says Chief Science Officer and Chief Executive Officer Erik Buntinx, psychiatrist, who was first to identify and report the beneficial clinical effects of PNB01 in patients.
Source: PharmaNeuroBoost
Tags: research
Bookmark this:
